Cardiovascular Endpoint

An objective morbid condition or cause of death linked to cardiovascular disease, used as an indicator in a clinical trial or reportable event
Examples Cardiovascular death, nonfatal myocardial infarction, hospitalization for heart failure, increase in blood pressure, etc.
References in periodicals archive ?
June 8, 2015 /PRNewswire-USNewswire/ -- Treatment with sitagliptin, a DPP-4 inhibitor, versus placebo for median 3 years in 14,671 patients with type 2 diabetes (T2DM) and established cardiovascular (CV) disease showed non-inferiority for the primary composite cardiovascular endpoint of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS), and no increase in hospitalization for heart failure in the sitagliptin group.
In patients with the genetic profile AA at rs1967309, there was a 39% reduction in the composite cardiovascular endpoint with dalcetrapib compared to placebo.
Two DAD Study analyses, (2,20) a EuroSIDA review, (1) the SMART cardiovascular endpoint dissection, (3) and a combined analysis of the ESPRIT and SILCAAT interleukin 2 (IL-2) trials (37) discerned no link between CD4 count (measured various ways) and risk of cardiovascular disease (also measured various ways) (Table 1).
The independent safety monitoring board for the RECORD trial--a large, long-term clinical trial, which has been designed to look at cardiovascular outcomes in people with diabetes--reviewed an interim analysis of cardiovascular endpoint in all study participants, and determined that the study should be allowed to continue.
NASDAQ: SNTS) and VeroScience, LLC today announced that new analyses of cardiovascular endpoint data from a previously disclosed 52-week, randomized safety study with CYCLOSET([R]) (bromocriptine mesylate) tablets were published in the Journal of the American Heart Association (JAHA), an online publication.
During the 76-week treatment phase, the pre-specified adjudicated cardiovascular endpoint (defined as cardiovascular death, myocardial infarction, unstable angina or stroke) occurred in 16 anacetrapib-treated patients (2.
CYCLOSET did not increase the incidence of a composite cardiovascular endpoint relative to placebo.
The primary safety assessment will be determined by the analysis of non-inferiority to comparator drugs using a composite cardiovascular endpoint from a safety database pooled from the four Phase 3 trials.
The primary assessment of safety will be an analysis of non-inferiority to comparator drugs using a composite cardiovascular endpoint from a safety database pooled from all four Phase 3 trials.
The number of episodes of a common cardiovascular endpoint of cardiovascular mortality, non-fatal MI, or non-fatal stroke was 6 (2.
Assessment of safety will include an analysis of non-inferiority to comparator drugs using a composite cardiovascular endpoint from a safety database pooled from all four Phase 3 trials.
Full browser ?